Unigestion Holding Sa Neurocrine Biosciences Inc Transaction History

Unigestion Holding Sa

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$79.65 - $106.22 $776,348 - $1.04 Million	-9,747 Closed	0 $0
Q3 2021 Oct 14, 2021	BUY	$86.18 - $99.03 $77,217 - $88,730	896 Added 10.12%	9,747 $920,000
Q2 2021 Jul 29, 2021	SELL	$89.43 - $102.27 $70,291 - $80,384	-786 Reduced 8.16%	8,851 $858,000
Q1 2021 May 05, 2021	BUY	$87.57 - $119.4 $165,682 - $225,904	1,892 Added 24.43%	9,637 $937,000
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $113,330 - $141,262	-1,304 Reduced 14.41%	7,745 $742,000
Q3 2020 Nov 10, 2020	BUY	$96.16 - $135.15 $870,151 - $1.22 Million	9,049 New	9,049 $870,000

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Unigestion Holding Sa, based on Form 13F filings with the SEC.

Stay updated on Unigestion Holding Sa with notifications on news.